Methods for identifying and isolating CD8 T cells that produce interleukin-13 upon activation are provided. The present methods leverage one or more newly-identified biomarkers to identify such CD8 T cells and, in certain cases, sort the same. Certain methods comprise obtaining a sample from a mammal, quantifying a level of expression of one or more biomarkers therein, and determining if the level of expression is elevated as compared, wherein an elevated expression level is indicative of an active disease state. Antisera and antibodies are also provided. In particular, an anti-C10orf128 antiserum formulated against a particular peptide is provided, such anti-C10orf128 antiserum characterized in that it identifies a subset of CD8 T cells that produce interleukin-13 upon activation.

The disclosure is in the field of cell therapy, more in particular, stem cell transplantation therapy. The disclosure provides methods and compositions for improving the efficacy of stem cell transplantation therapy by reducing the inflammatory activity of a stem cell transplant. More in particular, the disclosure provides a method for preparing a stem cell transplant with reduced inflammatory activity comprising a step of suspending a composition comprising stem cells in a fibrinogen-depleted plasma and/or in a fibrinogen and C-reactive protein-depleted plasma.

The present invention relates to processes and systems for preparing nanoparticles, cellular or viral membranes and/or cellular or viral membrane coated nanoparticles using or comprising, inter alia, a multi-inlet vortexing reactor, tangential flow filtration (TFF) and/or a high shear fluid processor such as a microfluidizer (or a microfluidizer processor). The present invention also relates to the nanoparticles, cellular or viral membranes and/or cellular or viral membrane coated nanoparticles prepared by the present processes and systems, and the uses and/or applications of the nanoparticles, cellular or viral membranes and/or cellular or viral membrane coated nanoparticles.

The present disclosure provides modified EGFR peptides useful in genetically-modified cells to allow for selection and enrichment of those cells expressing the modified EGFR peptide. For example, isolation of genetically-modified cells expressing a modified EGFR peptide can allow for selection of cells that co-express a chimeric antigen receptor or exogenous T cell receptor. In those instances wherein the genetically-modified cells present adverse effects when administered to a subject, the modified EGFR finds farther use as a suicide gene upon administration of an anti-EGFR antibody, leading to depletion of the ,genetically-modified cells. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the modified EGFR peptides, and methods of administering compositions comprising the modified EGER peptides to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.

An antibody that binds a CD8α hinge region, wherein the antibody is capable of binding to a functional exogenous receptor, and wherein the functional exogenous receptor comprises an extracellular domain, the CD8α hinge region, a transmembrane domain, and an intracellular signaling domain.

The present invention has as its object to find out new conditions that make it possible to induce cell death of non-cardiomyocytes or undifferentiated stem cells more completely and to select cardiomyocytes only.

In order to achieve this object, there are provided in the present application: a cell culture medium for use in inducing cell death of undifferentiated stem cells, wherein the cell culture medium is free of glutamine in the amino acid profile; and also a method for inducing cell death of non-cardiomyocytes by performing cell culture in said cell culture medium. Further provided in this application are: a cell culture medium for use in selecting cardiomyocytes, wherein the cell culture medium is supplemented with lactate, pyruvate or a fatty acid, free of sugar, and free of glutamine in the amino acid profile; and also a method for selecting cardiomyocytes by culturing a mixture of cardiomyocytes and non-cardiomyocytes in said cell culture medium.

An object of the invention is to provide a means for accomplishing inactivation of a pathogen in a blood sample containing red blood cells and platelets together, as well as sufficiently reducing the hemolysis rate of the red blood cell product finally obtained.

The means is to irradiate ultraviolet ray to a blood sample containing red blood cells and platelets in the presence of a hemolysis inhibitor and a surfactant having an HLB value of 13 or greater and having the number of oxyethylene groups of a hydrophilic portion in the molecular structure of 20 or greater when producing a blood product containing red blood cells and platelets.

Provided is a cell trapping method for selectively trapping a specific cell included in a cell-containing solution at a filter surface by filtering a liquid, and the method includes a step of draining a liquid for n (n is a natural number) times, in which from the first step of draining the liquid to the n-th step of draining the liquid, a liquid surface of the liquid in the introduction region on the filter is maintained at a predetermined liquid surface height, and when the n-th step of draining the liquid is completed, the discharging of the liquid from the cell trapping device is stopped in a state where the liquid surface is at a predetermined height in the filter.

The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains. Preferably, the specificity and mode of action of the anti-CD4 antibodies are not affected by the modification(s).

The present invention has an object to solve the problem in a method for separating nucleated cells from a cell-containing fluid using a cell separation filter. Specifically, the present invention provides a cell separation filter and a method for preparing cells using a cell separation filter, which are capable of reducing unnecessary cell contamination in a nucleated cell fraction without needs of designing non-woven fabrics to suit cell species to be recovered. The present invention also provides a cell separation filter and a method for preparing cells using the filter capable of improving the recovery yield of nucleated cells. The present invention provides a cell separation filter comprising: a container having an inlet and an outlet, an adsorbent filled in the container, and a partition having an opening, the partition separating the adsorbent. The present invention also provides a method for preparing nucleated cells including the steps of: introducing a cell-containing fluid through the inlet of the cell separation filter to contact the cell-containing fluid with the adsorbent; and recovering a nucleated cell fraction from the filter.